JPM
JPMorgan Chase & Co.
stock NYSE

Yes. We have retired early and are living off the dividends from our taxable account. They cover our basic expenses and are increasing faster than long-term inflation.
Because we are recently retired early, the portfolio is in the process of migrating from Dividend Growth to Dividend Income.
Growth: GOOGL AMZN AAPL NVDA V
Dividend Growth: HD LOW PEP PG CVX AMP BX FITB JPM PRU STT AMGN JNJ CAT CMI LMT UNP AVGO MSFT QCOM EGP ATO CPK ES EVRG NEE WEC
Dividend Income: VZ BKE CNQ EPD HESM MPLX AB AFG O VICI EOI EOS GPIQ QQQH QQQI SPYH SPYI UTG
This is our taxable account only. Retirement accounts can’t be touched for a few years still.

ah, i remember that. they had a great checking account product at the time, so i had opened an account. lo and behold, within a month i was a JPM Chase customer.

I went to cash on April 8 and am more than half back into VTI, plus grabbed NVDA, JPM, TSM, ARM, SHOP, FSLR, ENPH, and COIN while they were down. Have significantly improved my cost basis and back to business as usual: DCA. Still have dry powder if shit hits the fan again.

You might want to check out NEOS cc funds. They are better than Jepi and Jepq as far as growth potential with a healthier more reliable dividend than JPM funds. Their SPYI and QQQI cc funds track SPX and QQQ respectively. Blending them into your mix might give more yield/growth and beta along with SCHD.

UNH: Very interesting insiders are making large purchases just 48 hours ago. Ive bought 250 shares, and calls when it hit $255, what are you doing?
Timothy Flynn, a director at UnitedHealth Group Inc. (NYSE:UNH), purchased 1,533 shares of the company's common stock on May 14, totaling approximately $491,786. The shares were acquired at a price of $320.80 each. This insider purchase comes as UNH stock has declined significantly, down about 46% over the past year. According to InvestingPro offers 15+ additional premium tips and a comprehensive Pro Research Report for UNH, helping investors make more informed decisions.
In other recent news, UnitedHealth Group's earnings and revenue figures have been a focal point for analysts. Raymond (NSE:RYMD) James has adjusted its future earnings per share (EPS) estimates downward, citing concerns over the quality and recurrence of earnings, particularly after excluding $4 billion in one-time gains from 2024. The revised estimates project an adjusted EPS of $20 for 2025 and $23 for 2026. Meanwhile, RBC Capital Markets reduced its price target for UnitedHealth to $355, while maintaining an Outperform rating, due to revised EPS estimates and valuation concerns amid increased Department of Justice (DOJ) activity.
Wolfe Research, however, maintained its $501 price target and Outperform rating, despite the ongoing DOJ investigation into potential Medicare fraud. JPMorgan (NYSE:JPM) also revised its price target to $405, reflecting recent leadership changes and the suspension of 2025 guidance. The analyst at JPMorgan projects a 2025 EPS of $22.26 and anticipates a 10% growth in 2026. The DOJ's investigation, focusing on Medicare Advantage billing practices, has been ongoing since last summer, with specific allegations yet to be disclosed. Despite these challenges, analysts remain cautiously optimistic about UnitedHealth's long-term prospects.

Another quarterly rundown on 13Fs and institutional ownership. All this information is available on [Palantir Technologies Inc 13F Hedge Fund and Asset Management Owners - WhaleWisdom.com](https://whalewisdom.com/stock/pltr). Waited until the 16th this time, no but late reporting stragglers except CTC LLC who bought 450K shares and almost 1.5M calls and puts (which as mentioned below seems to be the strategy with calls and puts). Norges Bank (a large buyer last time) has submitted its 13F form to the SEC pursuant to a request for confidential treatment so not buys/sells are made to be made public at this time. (Hmmmmmm....TSLAs largest holder is Norges Bank as of 12-31...hmmmmm)
So what have we got? 64,746,910 shares were sold and 92,579,834 shares were bought during that volatile quarter. Based upon that volatility I don't think I can even estimate what an approximant average price is so I picked end date of $84.40 giving us a total inflow of $2.35B while the share price during that 1st quarter raised PLTR's market cap by $20B (roughly $8.91 on 2.26B shares). For comparison approximately $3.4B was bought by institutions last quarter.
Only 2 seller sold over 2M shares this last quarter, and they were the same top 2 the quarter before, Vanguard and Renaissance Technologies. Vanguard sold 22M, leaving them with 198M. Vanguard sold 22M shares last quarter as well. Renaissance Tech sold 6.5M (after selling 15M last quarter). For Renaissance Tech, it stills remains there top holding around 2% so I imagine they are selling due to their investment mandate restrictions (or again, it may be pure copium).
Over 15 buyers bought over 2M shares for comparison, not including a possibly buy by Norges Bank, who as mentioned above is not disclosing activity. Biggest Buyers Blackrock with with15.8M (14M in the quarter before) JPM with 7.5M, Nuveen making an initial purchase of 6.1M, DE Shaw with 5.9M and Price T Rowe with 4. When it came to call/put action, most of the big names seem to use it at arbitrage (Susquehanna, Peak6, SG Americas, IMC Chicago, Jane Street)
Regarding Notable Funds/Institutions. Unfortunately, Duquense Family Office LLC sold all their PLTR (41,710 shares). Stanley Druckenmiller was an early champion of PLTR who sold all his shares back in Q2 2023 before buying back and now (well as of March 31) is on the sidelines again. Wedbush (where Dan Ives is Managing Director, Global Head of Technology Research) made PLTR there second largest purchase by $ (and the only one in their top 5 that wasn't an EFT. They bought 53,470 shares and is now their 17th biggest holding. (So over the last 3 quarters it has gone from 67th to 25th to 17th).  As mentioned earlier, Renaissance who have been a huge bull since the beginning did sell a sizeable amount. However, it is still there top holding so I'm confident they are selling due to investment mandate rather then a change in attitude. Thanks for reading! PTFB as the kids say these days.

why BRK but not JPM?

Thing about CRWV is they need money this year, lots of money, $23 billion to be exact.
Enter Goldman, Morgan Stanley, JPM and others, doing ATMs and convertibles will generate a ton of fees. This is why they're going to push CRWV to the stratosphere and create generational bagholders, mostly institutional bagholders.
First they'll push it to $100, then we get the "leaks" and stories/rumors about deals with so and so and their analysts will put astronomical price targets and pound the table about how it's the greatest company not named Nvidia. Then once it reaches $150 or so, they will do the ATMs/convertibles deals.

PLTR, AMZN, JPM, HD, CMI

!banbet JPM 300 2m

Point is at any given time Airbus could have planes fall out of the air and there are smoking gun emails it was a known risk, JPM could have any number of issues. What I mean is people instinctively sell because "company is doomed" and take gigantic loses on their shares, when it is almost never the case and 100% of large cap companies can and will have crises.

I own a large portfolio of individual investment grade issues (BAC, ALL, NEE, WFC, USB, JPM, PSA, COF, CMS, ALL, Entergy, MS, etc.. Not applicable to you but I use the ETFs for shorting to hedge the above because of their liquidity.

Yes. We have retired early and are living off the dividends from our taxable account. They cover our basic expenses and are increasing faster than long-term inflation.
Because we are recently retired early, the portfolio is in the process of migrating from Dividend Growth to Dividend Income.
Growth: GOOGL AMZN AAPL NVDA V
Dividend Growth: HD LOW PEP PG CVX AMP BX FITB JPM PRU STT AMGN JNJ CAT CMI LMT UNP AVGO MSFT QCOM EGP ATO CPK ES EVRG NEE WEC
Dividend Income: VZ BKE CNQ EPD HESM MPLX AB AFG O VICI EOI EOS GPIQ QQQH QQQI SPYH SPYI UTG
This is our taxable account only. Retirement accounts can’t be touched for a few years still.

ah, i remember that. they had a great checking account product at the time, so i had opened an account. lo and behold, within a month i was a JPM Chase customer.

I went to cash on April 8 and am more than half back into VTI, plus grabbed NVDA, JPM, TSM, ARM, SHOP, FSLR, ENPH, and COIN while they were down. Have significantly improved my cost basis and back to business as usual: DCA. Still have dry powder if shit hits the fan again.

You might want to check out NEOS cc funds. They are better than Jepi and Jepq as far as growth potential with a healthier more reliable dividend than JPM funds. Their SPYI and QQQI cc funds track SPX and QQQ respectively. Blending them into your mix might give more yield/growth and beta along with SCHD.

UNH: Very interesting insiders are making large purchases just 48 hours ago. Ive bought 250 shares, and calls when it hit $255, what are you doing?
Timothy Flynn, a director at UnitedHealth Group Inc. (NYSE:UNH), purchased 1,533 shares of the company's common stock on May 14, totaling approximately $491,786. The shares were acquired at a price of $320.80 each. This insider purchase comes as UNH stock has declined significantly, down about 46% over the past year. According to InvestingPro offers 15+ additional premium tips and a comprehensive Pro Research Report for UNH, helping investors make more informed decisions.
In other recent news, UnitedHealth Group's earnings and revenue figures have been a focal point for analysts. Raymond (NSE:RYMD) James has adjusted its future earnings per share (EPS) estimates downward, citing concerns over the quality and recurrence of earnings, particularly after excluding $4 billion in one-time gains from 2024. The revised estimates project an adjusted EPS of $20 for 2025 and $23 for 2026. Meanwhile, RBC Capital Markets reduced its price target for UnitedHealth to $355, while maintaining an Outperform rating, due to revised EPS estimates and valuation concerns amid increased Department of Justice (DOJ) activity.
Wolfe Research, however, maintained its $501 price target and Outperform rating, despite the ongoing DOJ investigation into potential Medicare fraud. JPMorgan (NYSE:JPM) also revised its price target to $405, reflecting recent leadership changes and the suspension of 2025 guidance. The analyst at JPMorgan projects a 2025 EPS of $22.26 and anticipates a 10% growth in 2026. The DOJ's investigation, focusing on Medicare Advantage billing practices, has been ongoing since last summer, with specific allegations yet to be disclosed. Despite these challenges, analysts remain cautiously optimistic about UnitedHealth's long-term prospects.

Another quarterly rundown on 13Fs and institutional ownership. All this information is available on [Palantir Technologies Inc 13F Hedge Fund and Asset Management Owners - WhaleWisdom.com](https://whalewisdom.com/stock/pltr). Waited until the 16th this time, no but late reporting stragglers except CTC LLC who bought 450K shares and almost 1.5M calls and puts (which as mentioned below seems to be the strategy with calls and puts). Norges Bank (a large buyer last time) has submitted its 13F form to the SEC pursuant to a request for confidential treatment so not buys/sells are made to be made public at this time. (Hmmmmmm....TSLAs largest holder is Norges Bank as of 12-31...hmmmmm)
So what have we got? 64,746,910 shares were sold and 92,579,834 shares were bought during that volatile quarter. Based upon that volatility I don't think I can even estimate what an approximant average price is so I picked end date of $84.40 giving us a total inflow of $2.35B while the share price during that 1st quarter raised PLTR's market cap by $20B (roughly $8.91 on 2.26B shares). For comparison approximately $3.4B was bought by institutions last quarter.
Only 2 seller sold over 2M shares this last quarter, and they were the same top 2 the quarter before, Vanguard and Renaissance Technologies. Vanguard sold 22M, leaving them with 198M. Vanguard sold 22M shares last quarter as well. Renaissance Tech sold 6.5M (after selling 15M last quarter). For Renaissance Tech, it stills remains there top holding around 2% so I imagine they are selling due to their investment mandate restrictions (or again, it may be pure copium).
Over 15 buyers bought over 2M shares for comparison, not including a possibly buy by Norges Bank, who as mentioned above is not disclosing activity. Biggest Buyers Blackrock with with15.8M (14M in the quarter before) JPM with 7.5M, Nuveen making an initial purchase of 6.1M, DE Shaw with 5.9M and Price T Rowe with 4. When it came to call/put action, most of the big names seem to use it at arbitrage (Susquehanna, Peak6, SG Americas, IMC Chicago, Jane Street)
Regarding Notable Funds/Institutions. Unfortunately, Duquense Family Office LLC sold all their PLTR (41,710 shares). Stanley Druckenmiller was an early champion of PLTR who sold all his shares back in Q2 2023 before buying back and now (well as of March 31) is on the sidelines again. Wedbush (where Dan Ives is Managing Director, Global Head of Technology Research) made PLTR there second largest purchase by $ (and the only one in their top 5 that wasn't an EFT. They bought 53,470 shares and is now their 17th biggest holding. (So over the last 3 quarters it has gone from 67th to 25th to 17th).  As mentioned earlier, Renaissance who have been a huge bull since the beginning did sell a sizeable amount. However, it is still there top holding so I'm confident they are selling due to investment mandate rather then a change in attitude. Thanks for reading! PTFB as the kids say these days.

why BRK but not JPM?

Thing about CRWV is they need money this year, lots of money, $23 billion to be exact.
Enter Goldman, Morgan Stanley, JPM and others, doing ATMs and convertibles will generate a ton of fees. This is why they're going to push CRWV to the stratosphere and create generational bagholders, mostly institutional bagholders.
First they'll push it to $100, then we get the "leaks" and stories/rumors about deals with so and so and their analysts will put astronomical price targets and pound the table about how it's the greatest company not named Nvidia. Then once it reaches $150 or so, they will do the ATMs/convertibles deals.